Cystic Fibrosis: New Insights into Therapeutic Approaches

Since the identification of Cystic Fibrosis (CF) as a disease in 1938 until 2012, only therapies to treat symptoms rather than etiological therapies have been used to treat the disease. Over the last few years, new technologies have been developed, and gene editing strategies are now moving toward a one-time cure. This review will summarize recent advances in etiological therapies that target the basic defect in the CF Transmembrane Receptor (CFTR), the protein that is mutated in CF. We will discuss how newly identified compounds can directly target mutated CFTR to improve its function. Moreover, we will discuss how proteostasis regulators can modify the environment in which the mutant CFTR protein is synthesized and decayed, thus restoring CFTR function. The future of CF therapies lies in combinatory therapies that may be personalized for each CF patient.

• Publication year

  2020

• Venue

  Current Respiratory Medicine Reviews

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/1573398X15666190702151613
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• CFTR modulator theratyping: Current status, gaps and future directions.

  2019cited by this paper
• Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations.

  2019cited by this paper
• Factors influencing readthrough therapy for frequent cystic fibrosis premature termination codons

  2018cited by this paper
• Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.

  2018cited by this paper
• Ivacaftor CFTR Potentiator Therapy is Efficient for Pancreatic Manifestations in Cystic Fibrosis

  2018cited by this paper
• HDAC Inhibitors Rescue Multiple Disease-Causing CFTR Variants

  2018cited by this paper
• Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies.

  2018cited by this paper
• The structural basis of cystic fibrosis.

  2018cited by this paper
• Lessons learned from lung and liver in-vivo gene therapy: implications for the future

  2018cited by this paper
• Correcting the F508del-CFTR variant by modulating eukaryotic translation initiation factor 3–mediated translation initiation

  2018cited by this paper
• Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis

  2018cited by this paper
• Chaperone-Independent Peripheral Quality Control of CFTR by RFFL E3 Ligase.

  2018cited by this paper
• Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis.

  2018cited by this paper
• A highly specific SpCas9 variant is identified by in vivo screening in yeast

  2018cited by this paper
• Innovative Therapeutic Strategies for Cystic Fibrosis: Moving Forward to CRISPR Technique

  2018cited by this paper
• The changing epidemiology and demography of cystic fibrosis.

  2017cited by this paper
• Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del

  2017cited by this paper
• CRISPR Editing Technology in Biological and Biomedical Investigation

  2017cited by this paper
• Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.

  2017cited by this paper
• Thymosin α1 represents a potential potent single molecule-based therapy for cystic fibrosis

  2017cited by this paper
• The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis

  2017cited by this paper
• Precise insertion and guided editing of higher plant genomes using Cpf1 CRISPR nucleases

  2017cited by this paper
• Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation

  2017cited by this paper
• Genetic therapies for cystic fibrosis lung disease

  2017cited by this paper
• New horizons for cystic fibrosis treatment

  2017cited by this paper
• Use of a High-Throughput Phenotypic Screening Strategy to Identify Amplifiers, a Novel Pharmacological Class of Small Molecules That Exhibit Functional Synergy with Potentiators and Correctors

  2017cited by this paper
• Strategies for the etiological therapy of cystic fibrosis

  2017cited by this paper
• Roadmap for an early gene therapy for cystic fibrosis airway disease

  2017cited by this paper
• Ataluren in cystic fibrosis: development, clinical studies and where are we now?

  2017cited by this paper
• Gene delivery to the lungs: pulmonary gene therapy for cystic fibrosis

  2017cited by this paper
• Epidemiology of CF: How registries can be used to advance our understanding of the CF population.

  2017cited by this paper
• Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.

  2017cited by this paper
• Cysteamine re-establishes the clearance of Pseudomonas aeruginosa by macrophages bearing the cystic fibrosis-relevant F508del-CFTR mutation

  2017cited by this paper
• Tezacaftor–Ivacaftor in Residual‐Function Heterozygotes with Cystic Fibrosis

  2017cited by this paper
• Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis

  2016cited by this paper
• CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis

  2016cited by this paper
• Genetic medicines for CF: Hype versus reality

  2016cited by this paper
• From the endoplasmic reticulum to the plasma membrane: mechanisms of CFTR folding and trafficking

  2016cited by this paper
• Cystic fibrosis

  2016cited by this paper
• Engineering Synthetic Gene Circuits in Living Cells with CRISPR Technology.

  2016cited by this paper
• Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.

  2016cited by this paper
• A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR

  2016cited by this paper
• Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids

  2016cited by this paper
• Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives

  2016cited by this paper
• Regulatory Crosstalk by Protein Kinases on CFTR Trafficking and Activity

  2016cited by this paper
• Natural Compounds as Therapeutic Agents in the Treatment Cystic Fibrosis

  2016cited by this paper
• From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations

  2016cited by this paper
• Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis

  2016cited by this paper
• Drug combination therapy increases successful drug repositioning.

  2016cited by this paper
• Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics

  2016cited by this paper
• Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial

  2015cited by this paper
• Resveratrol increases F508del-CFTR dependent salivary secretion in cystic fibrosis mice

  2015cited by this paper
• ΔF508 CFTR interactome remodeling promotes rescue of Cystic Fibrosis

  2015cited by this paper
• Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed Drugs Elicits Cell-Lethal Autophagy and Therapeutic Benefit.

  2015cited by this paper
• Hallmarks of therapeutic management of the cystic fibrosis functional landscape.

  2015cited by this paper
• Origins of cystic fibrosis lung disease.

  2015cited by this paper
• Resveratrol ameliorates abnormalities of fluid and electrolyte secretion in a hypoxia‐Induced model of acquired CFTR deficiency

  2015cited by this paper
• Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease.

  2015cited by this paper
• Ibuprofen rescues mutant cystic fibrosis transmembrane conductance regulator trafficking.

  2015cited by this paper
• Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

  2015cited by this paper
• Personalized medicine: Time for one-person trials

  2015cited by this paper
• Posters

  2015cited by this paper
• Cystic fibrosis genetics: from molecular understanding to clinical application

  2014cited by this paper
• Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation.

  2014cited by this paper
• Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation

  2014cited by this paper
• Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.

  2014cited by this paper
• Identification of Resveratrol Oligomers as Inhibitors of Cystic Fibrosis Transmembrane Conductance Regulator by High-Throughput Screening of Natural Products from Chinese Medicinal Plants

  2014cited by this paper
• A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.

  2014cited by this paper
• Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.

  2014cited by this paper
• Casein kinase: the triple meaning of a misnomer.

  2014cited by this paper
• Kinase CK2 inhibition: an update.

  2013cited by this paper
• Control of cystic fibrosis transmembrane conductance regulator membrane trafficking: not just from the endoplasmic reticulum to the Golgi

  2013cited by this paper
• Disease-relevant proteostasis regulation of cystic fibrosis transmembrane conductance regulator

  2013cited by this paper
• Alternative Splicing of In‐Frame Exon Associated with Premature Termination Codons: Implications for Readthrough Therapies

  2013cited by this paper
• Resveratrol Enhances Airway Surface Liquid Depth in Sinonasal Epithelium by Increasing Cystic Fibrosis Transmembrane Conductance Regulator Open Probability

  2013cited by this paper
• Novel pharmacological strategies to treat cystic fibrosis.

  2013cited by this paper
• Personalised medicine for cystic fibrosis: treating the basic defect

  2013cited by this paper
• Detection of Phospho-Sites Generated by Protein Kinase CK2 in CFTR: Mechanistic Aspects of Thr1471 Phosphorylation

  2013cited by this paper
• Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients.

  2013cited by this paper
• A functional CFTR assay using primary cystic fibrosis intestinal organoids

  2013cited by this paper
• Pulmonary drug delivery: from generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges.

  2013cited by this paper
• Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on ΔF508 cystic fibrosis transmembrane conductance regulator

  2012cited by this paper
• A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference.

  2012cited by this paper
• CFTR biomarkers: time for promotion to surrogate end-point

  2012cited by this paper
• Requirements for efficient correction of ΔF508 CFTR revealed by analyses of evolved sequences.

  2012cited by this paper
• Sildenafil Acts as Potentiator and Corrector of CFTR but Might be not Suitable for the Treatment of CF Lung Disease

  2012cited by this paper
• CFTR: folding, misfolding and correcting the ΔF508 conformational defect.

  2012cited by this paper
• Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis

  2011cited by this paper
• A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

  2011cited by this paper
• Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

  2011cited by this paper
• High-throughput screening of libraries of compounds to identify CFTR modulators.

  2011cited by this paper
• Emergent properties of proteostasis in managing cystic fibrosis.

  2011cited by this paper
• Contribution of Casein Kinase 2 and Spleen Tyrosine Kinase to CFTR Trafficking and Protein Kinase A-Induced Activity

  2011cited by this paper
• Adeno-associated virus for cystic fibrosis gene therapy.

  2011cited by this paper
• Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.

  2010cited by this paper
• Cystic fibrosis transmembrane regulator fragments with the Phe508 deletion exert a dual allosteric control over the master kinase CK2.

  2010cited by this paper
• Peripheral Protein Quality Control Removes Unfolded CFTR from the Plasma Membrane

  2010cited by this paper
• Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition

  2010cited by this paper
• Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening

  2010cited by this paper
• Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes.

  2010cited by this paper

• No citing papers are available for this paper.